Naslov
SARS-CoV-2 neutralization assay – reliable tool for assessing therapeutic antibody quality

Autori
Ravlić, Sanda ; Hećimović, Ana ; Kurtović, Tihana ; Ivančić Jelečki, Jelena ; Forčić, Dubravko ; Slović, Anamarija ; Kurolt, Ivan Christian ; Mačak Šafranko, Željka ; Mušlin, Tatjana ; Rnjak, Dina ; Jakšić, Ozren ; Sorić, Ena ; Džepina, Gorana ; Đaković Rode, Oktavija ; Kujavec Šljivac, Kristina ; Vuk, Tomislav ; Jukić, Irena ; Markotić, Alemka ; Halassy, Beata

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
16th Vaccine Congress / - Riva del Garda, Italy, 2022, 35-35

Skup
16th Vaccine Congress

Mjesto i datum
Riva del Garda, Italija, 12.09.2022. - 14.09.2022

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Covid19 ; Sars-CoV-2 neutralization assay ; wild type virus

Sažetak
During the COVID-19 pandemic, much effort has been made to investigate SARS-CoV-2–specific antibodies as possible therapeutic agents. During that challenging time we are dealing with a new and insufficiently know pathogen, when reagents, standards and methodologies for antibody characterization are lacking, and are developed in parallel with therapy, making it difficult to properly asses and compare the results of convalescent plasma usage within the individual trials. At present, no conclusions can be drawn due to the lack of standardization in antibody assessments. Here we describe an approach of establishing antibody characterization in emergent times which would, if followed, enable comparison of results from different studies. We established an assay of wild-type SARS-CoV-2 neutralization, as the most relevant for antibody protectivity. To ensure the maximal reproducibility, we used a banking system of its biological components - a challenge virus, cells and an anti-SARS-CoV-2 antibody in-house standard, calibrated to the First WHO International Standard immediately upon its availability. Consequently, all collected serological data were retrospectively expressed in an internationally comparable way. The neutralizing antibodies (NAbs) among convalescents ranged from 4 to 2869 IUmL-1, being in significant positive correlation to the disease severity. NAbs decline in convalescents was on average 1.4-fold in a one-month period. Heat-inactivation of sera samples resulted in a 2.3-fold decrease of NAb titres in comparison to the native sera, implying significant complement activating properties of SARS-CoV-2 specific antibodies. The monitoring of NAb titres in the sera of immunocompromised COVID- 19 patients that lacked their own antibodies evidenced the successful transfusion of antibodies by the COVID-19 convalescent plasma units with NAb titres of 35 IUmL-1 or higher. Results have been published in Ravlić, Hećimović et al. Front. Immun. 2022 ; 13:816159. https://doi.org/10.3389/fimmu.2022.816159

Izvorni jezik
Engleski

Znanstvena područja
Biologija, Interdisciplinarne prirodne znanosti, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)

POVEZANOST RADA